Annual Gene Therapy Analytical Development Europe on May 20-22, 2025 in London, United Kingdom

The 6th Gene Therapy Analytical Development Summit Europe is the premier platform for advancing gene therapy analytics, empowering you to overcome challenges and fast-track therapies through IND/IMPD filings, clinical trials, and regulatory approvals.

With the gene therapy field progressing toward late-stage development, and hurdles like Rocket Pharma's KRESLADI rejection spotlighting critical gaps in CMC data, this summit provides timely, industry-focused insights tailored for the European market.

Join 24+ expert speakers to tackle characterisation, stability studies, contamination risks, and comparability across vectors and diseases.

Network with biotech, pharma, the MHRA and British Pharmacopoeia, share innovative solutions, and shape the future of gene therapy. Don't miss the only European event dedicated to driving analytical precision, QC strategy and delivering safe, effective therapies to patients worldwide.

URLs:

Tickets: https://go.evvnt.com/2872921-2?pid=10008

Brochure: https://go.evvnt.com/2872921-3?pid=10008

Time: 8:00 AM - 4:30 PM

Prices:

Conference + Workshop Day - Industry - Standard Pricing : GBP 3697.00,

Conference Only - Industry - Standard Pricing: GBP 2599.00,

Conference + Workshop Day - Service Provider - Standard Pricing : GBP 4397.00,

Conference Only - Service Provider - Standard Pricing: GBP 3099.00,

Conference + Workshop Day - Academic - Standard Pricing : GBP 3097.00,

Conference Only - Academic - Standard Pricing : GBP 2199.00

Speakers: Alicja Fiedorowicz, ATMP Working Group Scientific Lead Association of the British Pharmaceutical Industry, Anne douar, Independent Consultant, Claire Kerridge, Head of Gene Therapy MHRA, David Dobnik, Senior Research Associate National Institute of Biology, Fabien Dorange, Director - Analytical Sciences SparingVision, Femke De Keijzer Van De Water, Associate Director - Scientific, Cell Gene Therapy Analytics and Advanced Therapy Analytics Johnson and Johnson, Ishtiaq Khaliq, Lead Gene Therapy Molecular Biology Sciences, Analytical Development Sciences UCB, Isobel Searing, Director - Quality Control Replimune, Lara Nascimento, Strategic Technology and Collaborations Manager GlaxoSmithKline, Lily Li Lead, Scientist, Analytical Development AviadoBio, Lisa Kirkwood,Associate Director Analytical Development Aavantgarde Bio Srl., Michel Degueldre, Lead Gene Therapy Biophysical Sciences UCB, Natalie Palmer-Deverill Senior Scientist - Cell Assay Development MeiraGTx, Nathalie Van den Berghe Senior Scientist KULeuven, Oliver de Peyer Automation Scientist MeiraGTx, Pamela Whalley Associate Director, CMC. Complement Therapeutics Ltd Complement Therapeutics, Paulo Fernandes Senior Director, Technical Operations Spur Therapeutics, Scott Jeffers Chief Technology Officer GenSight Biologics, Simon Briggs Director - Advanced Analytics Orchard Therapeutics, Tim Farries Independent Consultant, Tony Bou Kheir Head of Analytical Development and Quality Control Purespring Therapeutics